Related Experiment Video
Updated: Jun 16, 2026
09:01
The Double-H Maze: A Robust Behavioral Test for Learning and Memory in Rodents
Published on: July 8, 2015
Controlled memory processes in questionable Alzheimer's disease: a view from neuroimaging research
Christine Bastin1, Nacer Kerrouche, Françoise Lekeu
1Cyclotron Research Center, University of Liège, Liège, Belgium.
Journal of Alzheimer'S Disease : JAD
|February 19, 2010
Summary
Early Alzheimer's disease (AD) impacts controlled memory, linked to reduced brain activity in specific regions. Automatic memory remains intact, highlighting key neural networks involved in early cognitive decline.
Area of Science:
- Neuroscience
- Cognitive Psychology
- Medical Imaging
Background:
- Alzheimer's disease (AD) involves progressive cognitive decline.
- Early detection of neural correlates is crucial for understanding AD.
- Controlled cognitive processes are particularly vulnerable in early AD.
Purpose of the Study:
- To investigate the neural basis of controlled memory deficits in early Alzheimer's disease.
- To differentiate brain activity patterns between patients who convert to AD and those who remain stable.
- To identify specific brain regions associated with impaired controlled memory processes.
Main Methods:
- Assessed controlled and automatic memory using the Process Dissociation Procedure in 50 questionable AD patients.
- Measured brain glucose metabolism via FDG-PET scans.
- Utilized voxel-based correlations to link cognitive performance with metabolic activity.
Main Results:
- Both converting and stable patients showed decreased controlled memory but preserved automatic memory.
- Reduced controlled memory correlated with lower activity in dorsomedial prefrontal and posterior cingulate cortices in early AD.
- In stable patients, impaired verbal memory correlated with reduced activity in the left anterior hippocampus.
Conclusions:
- A medial frontal-posterior cingulate network is critical for controlled episodic memory in early AD.
- Specific neural correlates differ between patients who progress to AD and those who remain stable.
- FDG-PET and cognitive assessments can identify early AD-related neural changes.
More Related Videos
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
11:01Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:14Role of Cerebellum and Prefrontal Cortex in Memory
The cerebellum, while traditionally associated with motor control, also plays a crucial role in memory, particularly in procedural memory, which involves learning motor tasks that become automatic through repetition. For example, studies have shown that when the cerebellum is damaged, individuals or animals lose the ability to learn conditioned motor responses, such as the conditioned eye-blink response in classical conditioning experiments with rabbits. This study demonstrates the cerebellum's...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...